Stockreport

Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF Cash Equivalents and Marketable Securities: $414.8 million at the start of 2026. Public Offering Proceeds: Raised an additional $161.8 million in net proceeds. Cash [Read more]